Evidence map›Paper›PMID 36915139›Full record

ArticleAlzheimer's research & therapy2023

Exploring the ATN classification system using brain morphology.

Nils Heinzinger, Anne Maass, David Berron, Renat Yakupov, Oliver Peters, Jochen Fiebach, Kersten Villringer, Lukas Preis, Josef Priller, Eike Jacob Spruth and 33 more

Open access · goldFull text read
In one paragraph

Article in Alzheimer's research & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Review
  5. Article
  6. Elevated NaInternational journal of molecular sciences · 2026
    Article
  7. Observational
  8. Elevated NabioRxiv : the preprint server for biology · 2025
    Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

43 authors at 14 institutions in 3 countries.

Nils HeinzingerGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany. nils.heinzinger@st.ovgu.de.
Anne MaassGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
David BerronGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Renat YakupovGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Oliver PetersGerman Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Jochen FiebachCenter for Stroke Research Berlin, Charité-Universitätsmedizin, Berlin, Germany.
Kersten VillringerCenter for Stroke Research Berlin, Charité-Universitätsmedizin, Berlin, Germany.
Lukas PreisDepartment of Psychiatry, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.
Josef PrillerGerman Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Eike Jacob SpruthGerman Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Slawek AltensteinGerman Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Anja SchneiderGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Klaus FliessbachGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Jens WiltfangGerman Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany.
Claudia BartelsDepartment of Psychiatry and Psychotherapy, University Medical Center Göttingen, University of Göttingen, Göttingen, Germany.
Frank JessenGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Franziska MaierDepartment of Psychiatry, Medical Faculty, University of Cologne, Cologne, Germany.
Wenzel GlanzGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Katharina BuergerGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Daniel JanowitzInstitute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.
Robert PerneczkyGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Boris-Stephan RauchmannDepartment of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany.
Stefan TeipelGerman Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
Ingo KillimannGerman Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
Doreen GöerßDepartment of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany.
Christoph LaskeGerman Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Matthias H MunkGerman Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Annika SpottkeGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Nina RoyGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Michael T HenekaGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Frederic BrosseronGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Laura DobischGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Michael EwersGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Peter DechentMR-Research in Neurosciences, Department of Cognitive Neurology, Georg-August-University Göttingen, Göttingen, Germany.
John Dylan HaynesBernstein Center for Computational Neuroscience, Charité-Universitätsmedizin, Berlin, Germany.
Klaus SchefflerDepartment for Biomedical Magnetic Resonance, University of Tübingen, Tübingen, Germany.
Steffen WolfsgruberGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Luca KleineidamGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Matthias SchmidGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Moritz BergerInstitute for Medical Biometry, University Hospital Bonn, Bonn, Germany.
Emrah Düzel *German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Gabriel Ziegler *German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Alzheimer’s Disease Neuroimaging Initiative
German Center for Neurodegenerative Diseases · DECharité - Universitätsmedizin Berlin · DELudwig-Maximilians-Universität München · DEOtto-von-Guericke University Magdeburg · DEUniversitätsmedizin Göttingen · DEUniversity of Rostock · DEHertie Institute for Clinical Brain Research · DELMU Klinikum · DEUK Dementia Research Institute · GBUniversity Hospital Bonn · DEUniversity of Bonn · DEUniversity of Cologne · DEUniversity of Göttingen · DEUniversity of Tübingen · DE

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
NIA NIH HHS U01 AG024904
6 · The paper itself

Abstract

backgroundThe NIA-AA proposed amyloid-tau-neurodegeneration (ATN) as a classification system for AD biomarkers. The amyloid cascade hypothesis (ACH) implies a sequence across ATN groups that patients might undergo during transition from healthy towards AD: A-T-N-➔A+T-N-➔A+T+N-➔A+T+N+. Here we assess the evidence for monotonic brain volume decline for this particular (amyloid-conversion first, tau-conversion second, N-conversion last) and alternative progressions using voxel-based morphometry (VBM) in a large cross-sectional MRI cohort.

methodsWe used baseline data of the DELCODE cohort of 437 subjects (127 controls, 168 SCD, 87 MCI, 55 AD patients) which underwent lumbar puncture, MRI scanning, and neuropsychological assessment. ATN classification was performed using CSF-Aβ42/Aβ40 (A+/-), CSF phospho-tau (T+/-), and adjusted hippocampal volume or CSF total-tau (N+/-). We compared voxel-wise model evidence for monotonic decline of gray matter volume across various sequences over ATN groups using the Bayesian Information Criterion (including also ROIs of Braak stages). First, face validity of the ACH transition sequence A-T-N-➔A+T-N-➔A+T+N-➔A+T+N+ was compared against biologically less plausible (permuted) sequences among AD continuum ATN groups. Second, we evaluated evidence for 6 monotonic brain volume progressions from A-T-N- towards A+T+N+ including also non-AD continuum ATN groups.

resultsThe ACH-based progression A-T-N-➔A+T-N-➔A+T+N-➔A+T+N+ was consistent with cognitive decline and clinical diagnosis. Using hippocampal volume for operationalization of neurodegeneration (N), ACH was most evident in 9% of gray matter predominantly in the medial temporal lobe. Many cortical regions suggested alternative non-monotonic volume progressions over ACH progression groups, which is compatible with an early amyloid-related tissue expansion or sampling effects, e.g., due to brain reserve. Volume decline in 65% of gray matter was consistent with a progression where A status converts before T or N status (i.e., ACH/ANT) when compared to alternative sequences (TAN/TNA/NAT/NTA). Brain regions earlier affected by tau tangle deposition (Braak stage I-IV, MTL, limbic system) present stronger evidence for volume decline than late Braak stage ROIs (V/VI, cortical regions). Similar findings were observed when using CSF total-tau for N instead.

conclusionUsing the ATN classification system, early amyloid status conversion (before tau and neurodegeneration) is associated with brain volume loss observed during AD progression. The ATN system and the ACH are compatible with monotonic progression of MTL atrophy.

trial registrationDRKS00007966, 04/05/2015, retrospectively registered.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAmyloid beta-PeptidesAmyloidogenic ProteinsBayes TheoremBiomarkersBrainCross-Sectional StudiesHumanstau ProteinsAmyloid beta-PeptidesAmyloidogenic ProteinsBiomarkerstau ProteinsAlzheimer’s diseaseAmyloidATNBiomarkerMemoryMRIVBMVoxel-based morphometry

Identifiers

PMID36915139
PMCPMC10009950
OpenAlexW4324129613

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read21
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.